Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines

Vaccine

Volumn 34, Issue 13, 2016, Pages 1559-1565

  Faust, Helena ^a   Toft, Lars ^b   Sehr, Peter ^c   Müller, Martin ^d   Bonde, Jesper ^e   Forslund, Ola ^f   Østergaard, Lars ^b   Tolstrup, Martin ^b   Dillner, Joakim ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e Mental Health Services CPH   (Denmark)

^f LUND UNIVERSITY   (Sweden)

Author keywords

Cervarix ; Gardasil ; HIV; HPV; Pseudovirions; Seroconversion

Indexed keywords

CROSS REACTING ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 73; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VACCINATION; VIRUS ATTACHMENT; VIRUS NEUTRALIZATION; ANTIBODY PRODUCTION; BLOOD; IMMUNIZATION; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; SERODIAGNOSIS;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CROSS REACTIONS; FEMALE; HIV SEROPOSITIVITY; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNIZATION SCHEDULE; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEROCONVERSION;

EID: 84960463991     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.02.019     Document Type: Article

References (23)

1. Herrero R., Gonzalez P., Markowitz L.E. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol 2015, 16(5):e206-e216.
2. Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans 2007, 90:1-689.
3. Lehtinen M., Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol 2013, 10(7):400-410.
4. Serrano B., Alemany L., Ruiz P.A., Tous S., Lima M.A., Bruni L., et al. Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China). Cancer Epidemiol 2014, 38(6):748-756.
5. Lowy D.R., Herrero R., Hildesheim A. Participants in the INCIwoPEfPHPVVT, primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. Lancet Oncol 2015, 16(5):e226-e233.
6. Schiller J.T., Castellsague X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl 5):F123-F138.
7. Schiller J.T., Lowy D.R. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009, 200(2):166-171.
8. World Health Organization.Dept.of Immunization Vaccines and Biologicals Human papillomavirus laboratory manual 2010, World Health Organization, Geneva, x, 113 pp. 1st ed.
9. Opalka D., Matys K., Bojczuk P., Green T., Gesser R., Saah A., et al. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol 2010, 17(5):818-827.
10. Sehr P., Rubio I., Seitz H., Putzker K., Ribeiro-Muller L., Pawlita M., et al. High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One 2013, 8(10):e75677.
11. Roberts C., Green T., Hess E., Matys K., Brown M.J., Haupt R.M., et al. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Hum Vaccin Immunother 2014, 10(8):2168-2174.
12. Faust H., Knekt P., Forslund O., Dillner J. Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin-coated beads. J Gen Virol 2010, 91(Pt 7):1840-1848.
13. Faust H., Jelen M.M., Poljak M., Klavs I., Ucakar V., Dillner J. Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types. J Clin Virol 2013, 56(4):336-341.
14. Toft L., Storgaard M., Muller M., Sehr P., Bonde J., Tolstrup M., et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis 2014, 209(8):1165-1173.
15. Toft L., Tolstrup M., Muller M., Sehr P., Bonde J., Storgaard M., et al. Comparison of the immunogenicity of Cervarix(R) and Gardasil(R) human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults. Hum Vaccine Immunother 2014, 10(5):1147-1154.
16. Bonde J., Rebolj M., Ejegod D.M., Preisler S., Lynge E., Rygaard C. HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 human papillomavirus genotype microarray system. BMC Infect Dis 2014, 14:413.
17. Buck C.B., Pastrana D.V., Lowy D.R., Schiller J.T. Efficient intracellular assembly of papillomaviral vectors. J Virol 2004, 78(2):751-757.
18. Eklund C., Unger E.R., Nardelli-Haefliger D., Zhou T., Dillner J. International collaborative proficiency study of Human Papillomavirus type 16 serology. Vaccine 2012, 30(2):294-299.
19. Grabowska K., Wang X., Jacobsson A., Dillner J. Evaluation of cost-precision rations of different strategies for ELISA measurement of serum antibody levels. J Immunol Methods 2002, 271(1-2):1-15.
20. Pastrana D.V., Buck C.B., Pang Y.Y., Thompson C.D., Castle P.E., FitzGerald P.C., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004, 321(2):205-216.
21. Grulich A.E., van Leeuwen M.T., Falster M.O., Vajdic C.M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370(9581):59-67.
22. Herrin D.M., Coates E.E., Costner P.J., Kemp T.J., Nason M.C., Saharia K.K., et al. Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus. Hum Vaccin Immunother 2014, 10(12):3446-3454.
23. Einstein M.H., Takacs P., Chatterjee A., Sperling R.S., Chakhtoura N., Blatter M.M., et al. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial. Hum Vaccin Immunother 2014, 10(12):3435-3445.